Find a Trial
|Status||OPEN TO ACCRUAL|
|Principal Investigator||O'Neil, Bert|
|Title||AN OPEN-LABEL, DOSE-FINDING AND PROOF OF CONCEPT STUDY OF THE PD-L1 PROBODY THERAPEUTIC, CX-072, AS MONOTHERAPY AND IN COMBINATION WITH YERVOY (IPILIMUMAB) OR WITH ZELBORAF (VEMURAFENIB) IN ANTI-PD-1/PD-L1 INHIBITOR NAIVE SUBJECTS WITH ADVANCED OR RECURRENT SOLID TUMORS OR LYMPHOMAS|
|Description||The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-001: PRObody CLinical Assessment In Man CX-072 clinical trial 001
CX-072 is a Probody? therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are proteolytically-activatable antibodies (Abs) designed to widen the therapeutic index by minimizing drug interaction with normal tissue while retaining anti-tumor activity. Probody therapeutics are "masked" to attenuate binding to target in healthy tissue but can become "unmasked" in the tumor microenvironment by tumor-specific protease activity.
PROBODY is a trademark of CytomX Therapeutics, Inc.
|Key Eligibility||In order to be eligible to take part in this trial, patients must meet the following criteria:|
|Applicable Disease Sites||Any Site|
|Participating Institutions||Indiana University (IU)|
|Contact||Anne E. Younger, RN||Phone: 317-274-0951|